Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
MicroRNAs in Cancer Therapy: Recent Advances and Prospects
share announcement

MicroRNAs in Cancer Therapy: Recent Advances and Prospects

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (20 January 2025) | Viewed by 1642

Special Issue Editor

Prof. Dr. Luis A. Salazar

E-Mail Website
Guest Editor
Center of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco 4811230, Chile
Interests: pharmacogenomics; pharmacoepigenetics; nanomedicine; toxicity of cancer chemotherapy; biological evaluation of natural compounds; cardiovascular diseases

Special Issue Information

Dear Colleagues,

The abnormal expression of microRNAs (miRNAs), which are regulatory small non-coding RNAs, occurs in pathological events such as cancer. Their extraordinary regulatory potential, which enables the regulation of entire signalling networks within the cells, makes them an interesting tool for the development of cancer therapeutics. The pattern of miRNAs expression can be correlated with the cancer type, stage, and other clinical variables. It has been demonstrated that miRNAs are implicated in almost all aspects of cancer biology, such as proliferation, apoptosis, invasion/metastasis, and angiogenesis. A number of miRNAs affect the growth of cancer cells in vitro and in vivo when overexpressed or inhibited. Therefore, cancer cell growth can be controlled by manipulating miRNAs.

In this Special Issue of Pharmaceutics, original articles and comprehensive reviews that present novel anticancer strategies with a focus on miRNAs exhibting experimentally proven therapeutic potential and that discuss recent advances in the technical development and clinical evaluation of miRNA-based therapeutic agents are welcome. These strategies should address the optimization of cancer therapies that could offer remarkable clinical value in the near future. We therefore encourage the submission of articles that focus on the development and validation of various novel anticancer approaches including, but not limited to, synthetic miRNA mimics such as the siRNA-like oligoribonucleotide duplex or chemically modified oligoribonucleotide, and strategies involving miRNA delivery using liposomes, viral vectors and nanoparticles, among others.

Prof. Dr. Luis A. Salazar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapy
  • miRNA mimics
  • miRNA delivery
  • oligoribonucleotide
  • siRNA-like oligoribonucleotide
  • drug delivery
  • therapy resistance
  • miRNA antagonists
  • viral vectors
  • LNA-modified oligonucleotides

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 5438 KiB  
Article
miR-195-5p Inhibits Colon Cancer Progression via KRT23 Regulation
by Emanuele Piccinno, Viviana Scalavino, Nicoletta Labarile, Raffaele Armentano, Gianluigi Giannelli and Grazia Serino
Pharmaceutics 2024, 16(12), 1554; https://doi.org/10.3390/pharmaceutics16121554 - 4 Dec 2024
Viewed by 952
Abstract
Background/Objectives: KRT23 was recently discovered as an epithelial-specific intermediate filament protein in the type I keratin family. Many studies have underlined keratin’s involvement in several biological processes as well as in the pathogenesis of different diseases. Specifically, KRT23 was reported to affect the [...] Read more.
Background/Objectives: KRT23 was recently discovered as an epithelial-specific intermediate filament protein in the type I keratin family. Many studies have underlined keratin’s involvement in several biological processes as well as in the pathogenesis of different diseases. Specifically, KRT23 was reported to affect the structural integrity of epithelial cells and to trigger cellular signaling leading to the onset of cancer. The aim of this study is to characterize a novel mechanism based on miR-195-5p/KRT23 in colorectal cancer. Methods: KRT23 mRNA and protein expression were characterized in FFPE sections from patients with CRC. The effects of miR-195-5p on KRT23 expression at the mRNA and protein levels were assessed by transient transfection experiments with mimic and inhibitor molecules. Cell attachment/detachment, migration, invasion, clone formation, and apoptosis were evaluated in human CRC cell lines after miR-195-5p mimic transfection. Results: We identified KRT23 as a putative target of miR-195-5p, a microRNA that we previously demonstrated to be reduced in CRC. We have proved the KRT23 expression deregulation in the tumoral section compared to adjacent normal mucosa in patients with CRC, according to the data derived from the public repository. We proved that the gain of miR-195-5p decreased the KRT23 expression. Conversely, we demonstrated that the inhibition of miR-195-5p led to an increase in KRT23 expression levels. We have demonstrated the in vitro effectiveness of miR-195-5p on CRC progression and that the in vivo intraperitoneal delivery of miR-195-5p mimic lowered colonic KRT23 mRNA and protein expression. Conclusions: These findings highlight a new regulatory mechanism by miR-195-5p in CRC affecting the keratin intermediate filaments and underline the miR-195-5p potential clinical properties. Full article
(This article belongs to the Special Issue MicroRNAs in Cancer Therapy: Recent Advances and Prospects)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop